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Summary
Background.— The role of cholesteryl ester transfer protein (CETP) in the development of
atherosclerosis is undergoing debate.
Aims.— In this prospective study, we sought to explore the role of the CETP Taq1B variant in
coronary artery disease risk, and its association with plasma lipid and apolipoprotein concen-
trations.
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hommes fumeurs.
Conclusion.— L’allèle B2 semble protéger contre l’athérosclérose coronaire lié à une augmen-
tation du C-LHD. Cet effet semble être plus signiﬁcatif chez les hommes non fumeurs.
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bbreviations
poA-1 apolipoprotein A-1
poB apolipoprotein B
ETP cholesteryl ester transfer protein
I conﬁdence interval
DL-C high-density lipoprotein cholesterol
DL-C low-density lipoprotein cholesterol
R odds ratio
.D. standard deviationackground
he concentration of HDL-C is associated inversely with the
isk of coronary heart disease [1]. Epidemiological studies
ave reported high levels of risk factors for coronary heart
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isease among Tunisian adults and children [2,3]. The CETP
lays a central role in the human metabolism of high-density
ipoprotein; it facilitates the exchange of triglycerides and
holesteryl esters between lipoprotein particles. The CETP
ene encompasses 16 exons and has been localized on
hromosome 16q21, adjacent to the lecithin—cholesterol
cyltransferase gene [4].
The role of CETP in atherogenesis is still under debate
5,6]. Through its function in the reverse cholesterol trans-
ort pathway, CETP is potentially antiatherogenic, because
t may facilitate the removal of excess cholesterol from the
ody via low-density lipoprotein receptor—mediated uptake
n the liver and excretion into the bile. Mutations in the CETP
ene are associated with increased coronary heart diseaseJ. Rejeb et al.
Methods.— DNA was extracted from 316 patients undergoing coronary angiography. The Taq1B
polymorphism was genotyped using polymerase chain reaction—restriction fragment length
polymorphism analysis. Lipid and apolipoprotein concentrations were measured by enzymatic
and nephelometric assays.
Results.— In our study population, the B2 allele frequency was 0.29. B2 allele carriers had
a signiﬁcantly higher high-density lipoprotein cholesterol (HDL-C) concentration than those
with the B1B1 genotype (1.041± 0.294 versus 0.995± 0.277; p = 0.039). After adjusting for age,
sex, smoking status, diabetes, hypertension and dyslipidaemia, the odds ratio (OR) for signif-
icant stenosis associated with the B2 allele was 0.82 (95% conﬁdence interval (CI) 0.60—0.97;
p = 0.039), suggesting that the B2 allele is associated with an 18% lower risk of signiﬁcant steno-
sis. This protective effect seemed to be more signiﬁcant in male nonsmokers (38% lower risk;
OR 0.62, 95%CI 0.29—0.92; p = 0.029). No signiﬁcant protective effects were observed in women
or male smokers.
Conclusion.— Our data suggest that the B2 allele is associated with higher concentrations of
HDL-C, which confer a protective effect with regard to coronary atherosclerosis. This effect
seems to be more signiﬁcant in men than in women and in nonsmokers than in smokers.
© 2008 Elsevier Masson SAS. All rights reserved.
Résumé En pathologies cardiovasculaires, il existe une controverse sur le rôle de la protéine
de transfert des esters de cholesterol (PTEC).
Objectifs.— Étude de la relation du polymorphisme Taq1B de la PTEC avec les paramètres
lipidiques et le risque coronarien.
Méthodes.— Nous avons recruté 316 patients documentés par coronarographie. Le génotypage
a été réalisé par la méthode de polymérisation en chaîne suivie de digestion par l’enzyme
de restriction Taq1B, les paramètres lipidiques et apolipoprotéiques ont été mesurés par des
méthodes enzymatiques et néphélométriques.
Résultats.— Dans notre population d’étude, la fréquence de l’allèle B2 a été de 0,29.
Les porteurs de l’allèle B2 ont présenté une concentration plus élevée du cholestérol des
lipoprotéines de haute densité (C-LHD) par rapport à B1B1 (1,041± 0,294mmol/L versus
0,995± 0,277mmol/L, p = 0,039). Après ajustement de l’âge, du sexe, du tabagisme, du dia-
bète, de l’hypertension et de la dyslipidémie, l’odds ratio (OR) de la sténose signiﬁcative
associée à l’allèle B2 a été de 0,82 (intervalle de conﬁance (IC) 95 % 0,60—0,97 ; p = 0,039)
donc l’allèle B2 semble diminuer de 18% le risque de sténose signiﬁcative. Cet effet pro-
tecteur semble être plus signiﬁcatif chez les hommes non fumeurs (38 % risque bas ; OR 0,62,
IC 95% 0,29—0,92 ; p = 0,029). Pas d’effet protecteur signiﬁcatif observé chez les femmes ou lesespite increased HDL-C concentrations [7]. On the other
and, as CETP may lower the concentration of atheropro-
ective HDL-C, it is often considered to be proatherogenic
8].
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tCETP Taq1B polymorphism and coronary artery disease
The CETP gene is highly polymorphic; several common
single nucleotide polymorphisms in the CETP gene have
been described. The most studied among these is the Taq1B
polymorphism, which has been shown to be a silent base
change affecting the 277th nucleotide in the ﬁrst intron
of the gene [9,10]. A polymorphism detected using Taq1
endonuclease has been shown, in various population stud-
ies, to be associated with plasma HDL-C concentration. The
allele containing the restriction site for the Taq1 endonu-
clease is called B1, while the allele without the restriction
site is called B2. Individuals with the B2 allele have been
found to have higher plasma HDL-C concentrations [11—16]
and investigators have suggested an association between
the polymorphism and coronary artery disease [15,16]. A
recent meta-analysis, which included 92 studies but did not
include a North African population, reported higher mean
concentrations of HDL-C and ApoA-I and a weak reduction in
coronary risk in individual carriers of the B2 allele [17]. How-
ever, other similar studies have reported conﬂicting results
[18—20], and few data have been reported on the screening
of this single nucleotide polymorphism in the CETP gene in
Tunisia [21]. It has been suggested that the association may
be population speciﬁc [22] and highly inﬂuenced by envi-
ronmental factors, such as alcohol consumption and tobacco
smoking [12,23].
The aim of our study was to determine the effects of
the Taq1B polymorphism on lipid and apolipoprotein con-
centrations, and on coronary artery disease, in a Tunisian
population.
Methods
Study population
In this prospective study, we recruited patients undergo-
ing coronary angiography because of myocardial infarction,
angina, thoracic pain or heart failure in the Cardiology
Department at Sahloul University Hospital, Sousse, Tunisia.
All patients were recruited between 2003 and 2007. Patients
were subdivided into two groups: those with coronary artery
disease and controls. Coronary artery disease patients were
those who had signiﬁcant coronary artery stenosis, which
was deﬁned as a luminal narrowing of more or equal to 50%
in at least one major coronary artery, as judged by coro-
nary angiography. Controls were those who had normal or
insigniﬁcant coronary angiographic ﬁndings (< 50%).
Data collection
Data on lifestyle factors were collected using an
interviewer—administered questionnaire. The ques-
tionnaire included details of personal history, presence of
disease, drug intake if any, cigarette smoking and alcohol
consumption. Patients taking lipid-lowering drugs were
excluded. Informed consent for the study was obtained
from all the patients. The study was approved by the local
medical ethics committee.Deﬁnition of cardiovascular risk factors
Cardiovascular risk factors were evaluated. Diabetes melli-
tus was deﬁned as fasting glucose more than 7mmol/L or
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urrently receiving antidiabetic medication. The smoking
tatus of an individual was assigned ‘yes’ if they were smok-
ng currently or had given up less than 3months previously.
ypertension was deﬁned as greater than 140/90mmHg
r currently on antihypertensive medication. Dyslipidaemia
as deﬁned as LDL-C concentration more or equal to
.1mmol/L and/or HDL-C concentration less or equal to
mmol/L and/or triglyceride concentration more or equal
o 1.71mmol/L.
easurement of plasma lipids and apolipoproteins
lood samples were collected from patients after a 12 h
vernight fast and before coronary angiography. Serum total
holesterol, triglyceride and HDL-C concentrations were
etermined by standard assays using the Synchrom CX7 Clini-
al System (Beckman, Fullerton, CA, USA). ApoA-I and ApoB
ere assayed using the IMMAGE Immunochemistry System
Beckman, Fullerton, CA, USA), based on immunonephelo-
etric quantitation. LDL-C concentrations were calculated
ith the Friedewald formula [24].
NA analysis
enomic DNA was isolated from peripheral blood leuco-
ytes by the salting out method [25]. CETP genotyping
as performed as described by Fumeron et al. [12],
ith some modiﬁcations. A 535 base pair fragment in
ntron of the CETP gene was ampliﬁed by polymerase
hain reaction in a DNA thermal cycler (LP× 2 Thermal
ycler, Thermo Electron Corporation, Milford, NE, USA).
he oligonucleotide primers used for ampliﬁcation were:
orward 5′-CACTAGCCCAGAGAGA-GGAGTGCC-3′ and reverse
′-CTGAGCCCAGCCGCACACTAAC-3′. Each ampliﬁcation was
erformed by using 100 ng of genomic DNA in a volume of
0L containing 8 pmoL of each oligonucleotide, 100M
eoxyribonucleotide triphosphate and 1U of Taq DNA poly-
erase (Promega, Madison, WI, USA). DNA templates were
enatured at 95 ◦C for 3min and then each polymerase chain
eaction was subjected to 30 cycles with a temperature
ycle consisting of 95 ◦C for 30 s, 60 ◦C for 30 s, 72 ◦C for
5 s, and, ﬁnally, an extension at 72 ◦C for 5min. The 535
ase pair polymerase chain reaction products were digested
ith 2U of Taq1 (Promega, Madison, WI, USA) at 65 ◦C for
h. Digested products were resolved by gel electrophoresis
2% agarose gel) and visualized by ethidium bromide stain-
ng. The digestion resulted in 174 base pair and 361 base
air fragments for the B1 allele and 535 base pair fragments
or the uncut B2 allele.
tatistical analyses
tatistical analyses were performed with Epi InfoTM soft-
are distributed by the World Health Organization. The
requencies of the allele genotypes among the patients
ere counted and compared by the chi-square test. The
iological variables were compared with one-way analy-
is of variance then by Student’s t test or Fisher’s exact
est and their values were reported as means± S.D. OR
ere calculated as a measure of the association of the
ETP Taq1B genotypes with the phenotypes. For each OR,
wo-tailed p-values and 95% CI were calculated; p was
onsidered to be signiﬁcant when it was less than 0.05.
djusted OR for potential confounders were determined
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Table 1 Clinical and biochemical characteristics of the study population.
Characteristics Coronary artery disease patients
(n = 212) Mean± SD or n (%)
Controls (n = 104)
Mean± SD or n (%)
p
Sex ratio 1.97 1.26 0.010
Age (years) 60.6± 10.6 59.4± 11.9 0.380
Smoker 120 (56.6) 47 (45.2) 0.013
Diabetic 73 (34.4) 23 (22.1) 0.001
Hypertension 97 (45.7) 46 (44.2) 0.353
History of myocardial infarction 91 (42.9) 13 (12.5) < 0.001
Dyslipidemia 33 (15.6) 9 (8.6) 0.027
Total cholesterol (mmol/L) 5.029± 1.192 5.025± 1.087 0.970
Triglyceride (mmol/L) 1.614± 1.117 1.340± 0.647 0.022
HDL-C (mmol/L) 0.961± 0.283 1.030± 0.276 0.040
LDL-C (mmol/L) 3.440± 1.167 3.330± 1.039 0.370
ApoA-I (g/L) 1.160± 0.379 1.290± 0.437 0.009
ApoB (g/L) 1.153± 0.376 1.110± 0.413 0.460
ApoB/ApoA-I 1.057± 0.493 0.920± 0.290 0.036
Triglyceride/HDL-C 5.630± 2.040 5.410± 1.890 0.430
ApoA-1: apolipoprotein A-1; ApoB: apolipoprotein B; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein
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Association of the CETP Taq1B allele with lipids
and apolipoproteins
Table 3 shows the association between the CETP Taq1B allele
and lipid and apolipoprotein concentrations. The mean
apoB/apoA-I ratio was signiﬁcantly lower in carriers of the
B2 allele than in patients with the B1B1 genotype.
In carriers of the B2 allele compared with those with
the B1B1 genotype, there was a statistically signiﬁcant
increase in HDL-C concentration (1.041± 0.294mmol/L
versus 0.995± 0.277mmol/L, respectively; p = 0.039)
and in ApoA-I concentration (1.27± 0.472 g/L versus
1.182± 0.334 g/L, respectively; p = 0.020). No other associ-
ations were detected between the CETP Taq1B allele and
lipids or apolipoproteins in our study population.
We carried out a sex-based subgroup analysis to fur-
ther investigate the effect of the two alleles on lipids
and apolipoproteins. The increase in HDL-C was greater in
men (p < 0.001) than in women (p = 0.034). Male carriers of
the B2 allele had a signiﬁcantly higher HDL-C concentra-
tion than men with the B1B1 genotype (1.009± 0.27mmol/L
versus 0.894± 0.20mmol/L, respectively; p < 0.001) and
a higher apoA-I concentration (1.186± 0.30 g/L versus
1.081± 0.31 g/L, respectively; p = 0.005). Male carriers of
Table 2 Frequency of Taq1B among study participants.
Genotypes Frequency, n (%)
Coronary artery disease
patients (n = 212)
Controls
(n = 104)cholesterol; S.D.: standard deviation.
sing logistic regression analysis and corresponding p-values
ere reported.
esults
opulation characteristics
he study comprised 316 patients (205 men and 111 women)
ndergoing coronary angiography because of myocardial
nfarction (n = 113), angina (n = 169), thoracic pain (n = 18)
r heart failure (n = 16). The causes of thoracic pain were
alvulopathy (n = 3), hypertensive cardiomyopathy (n = 2),
evere aortic disease and mitral insufﬁciency (n = 2), dilated
ardiomyopathy (n = 2) and psychiatric problems such as
nxiety or depression (n = 9). The causes of heart fail-
re were ischemic cardiopathy (n = 6), acute pulmonary
edema (n = 3), chronic pulmonary heart disease or chronic
bstructive pulmonary disease (n = 3) and hypertensive cri-
is (n = 4). The clinical and biochemical characteristics of
he patients are presented in Table 1. Compared with
he control group, the coronary artery disease group
ad higher proportions of smokers, patients with dyslipi-
emia, patients with a history of myocardial infarction
nd patients with diabetes, In addition, triglyceride con-
entrations and apoB/apoA-I ratios were also signiﬁcantly
igher in coronary artery disease patients than in controls.
onversely, HDL-C and apoA-I concentrations were signif-
cantly lower in coronary artery disease patients than in
ontrols.
enotype frequencieshe genotype frequencies of B1B1, B1B2 and B2B2 are shown
n Table 2. The calculated frequencies of the Taq1 B2 allele
n coronary artery disease patients and controls were 0.29
nd 0.34, respectively.
B1B1 104 (49) 45 (42.9)
B1B2 93 (44) 47 (45.4)
B2B2 15 (7) 12 (11.7)
B2 allele
frequency
0.29 0.34
CETP Taq1B polymorphism and coronary artery disease 633
Table 3 Association of CETP Taq1B allele with lipids and apolipoproteins.
B1B1 (n = 149)
Mean± S.D.
B2 allele a (n = 167)
Mean± S.D.
p
Total cholesterol (mmol/L) 4.943 ± 1.189 5.072 ± 1.180 0.206
HDL-C (mmol/L) 0.995 ± 0.277 1.041 ± 0.294 0.039
LDL-C (mmol/L) 3.354 ± 1.174 3.316 ± 1.059 0.690
Triglyceride (mmol/L) 1.474 ± 0.728 1.495 ± 1.19 0.158
ApoA-I (g/L) 1.182 ± 0.334 1.27 ± 0.472 0.020
ApoB (g/L) 1.14 ± 0.420 1.09 ± 0.400 0.055
ApoB/ApoA-I 0.964 ± 0.322 0.858 ± 0.596 0.017
Triglyceride/HDL-C 5.353 ± 2.04 5.325 ± 2.20 0.893
ApoA-1: apolipoprotein A-1; ApoB: apolipoprotein B; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein
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Dcholesterol; S.D.: standard deviation.
a B1B2 + B2B2.
the B2 allele also had a lower apoB/apoA-I ratio than men
with the B1B1 genotype (0.883± 0.30 versus 1.056± 0.31,
respectively; p = 0.030). These differences in lipids and
apolipoproteins between genotypes were not observed for
women.
Our data on smoking were limited to men, because all
the women in our study population were nonsmokers. Men
were divided into two groups according to smoking status
(Table 4). The mean concentration of HDL-C in smokers
was lower than that in nonsmokers (0.95 and 1.11mmol/L,
respectively). Smokers with the B2 allele had signiﬁcantly
higher HDL-C and apoA-I concentrations compared with
smokers with the B1B1 genotype; similarly, nonsmokers with
the B2 allele had signiﬁcantly higher HDL-C and apoA-I
concentrations compared with nonsmokers with the B1B1
genotype. The difference in HDL-C concentration between
carriers of the B2 allele and those with the B1B1 genotype
was more statistically signiﬁcant within the non-smoking
group (p < 0.001 versus p = 0.006 among smokers).Association of CETP Taq1B polymorphism with the
presence of stenosis
Among the non-smoking men in this study, there were 16
coronary artery disease patients and 15 controls. Table 5
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Table 4 Association of CETP Taq1B allele with lipids and apol
Male smokers
B1B1 (n = 80)
Mean± S.D.
B2 allele a (n = 93
Mean± S.D.
Total cholesterol (mmol/L) 4.936 ± 1.26 4.870 ± 1.18
HDL-C (mmol/L) 0.883 ± 0.21 0.969 ± 0.27
LDL-C (mmol/L) 3.360 ± 1.13 3.342 ± 1.37
Triglyceride (mmol/L) 1.494 ± 0.69 1.479 ± 0.85
ApoA-I (g/L) 1.034 ± 0.31 1.116 ± 0.29
ApoB (g/L) 1.100 ± 0.36 1.048 ± 0.43
ApoB/ApoA-I 1.036 ± 0.31 0.970 ± 0.31
Triglyceride/HDL-C 5.907 ± 2.23 5.617 ± 2.40
ApoA-1: apolipoprotein A-1; ApoB: apolipoprotein B; HDL-C: high-d
cholesterol; S.D.: standard deviation.
a B1B2 + B2B2.hows the crude and adjusted OR for signiﬁcant stenosis
n carriers of the B2 allele compared with those with the
1B1 genotype. After adjustment for age, sex, smoking sta-
us, diabetes, hypertension and dyslipidaemia, carriers of
he B2 allele had an 18% reduced risk of signiﬁcant steno-
is (OR 0.82, 95%CI: 0.6—0.97; p = 0.039). The B2 allele
requency was 0.315 in men and 0.298 in women. After
djustment for age, smoking status, diabetes, hypertension
nd dyslipidaemia, the OR for signiﬁcant stenosis associ-
ted with the B2 allele in men was 0.77 (95%CI: 0.57—0.91;
= 0.037). Among non-smoking men, those with the B2 allele
ad a 38% lower risk of signiﬁcant stenosis (OR 0.62, 95%CI:
.29—0.92; p = 0.029). There was no signiﬁcant reduction in
isk of signiﬁcant stenosis among female carriers of the B2
llele (OR 0.90, 95%CI: 0.08—1.19; p = 0.067).
iscussionhe role played by genetic polymorphisms in coronary
therosclerosis is far from being resolved. CETP poly-
orphism is one of the most studied polymorphisms in
therosclerosis. The impact of the gene/environmental
nteraction is difﬁcult to determine and genetic studies are
ipoproteins in male smokers and nonsmokers.
Male nonsmokers
) p B1B1 (n = 16)
Mean± S.D.
B2 allele a (n = 16)
Mean± S.D.
p
0.671 4.702 ± 0.74 4.808 ± 1.02 0.412
0.006 0.909 ± 0.17 1.125 ± 0.24 < 0.001
0.914 3.201 ± 0.74 3.153 ± 0.65 0.633
0.879 1.212 ± 0.81 1.481 ± 1.42 0.291
0.052 1.225 ± 0.25 1.373 ± 0.26 0.022
0.769 1.100 ± 0.35 1.073 ± 0.30 0.699
0.120 0.897 ± 0.26 0.781 ± 0.29 0.173
0.378 5.210 ± 1.86 4.960 ± 2.23 0.640
ensity lipoprotein cholesterol; LDL-C: low-density lipoprotein
634 J. Rejeb et al.
Table 5 Odds ratios for signiﬁcant stenosis (B2 allele compared with B1B1 genotype).
Crude OR Adjusted OR
OR 95%CI p OR 95%CI p
All patients (n = 316) 0.86 0.7—0.96 0.042 0.82a 0.60—0.97 0.039
Men (n = 205) 0.80 0.59—0.89 0.036 0.77b 0.57—0.91 0.037
Women (n = 111) 0.90 0.08—1.19 0.067 0.89b 0.12—1.22 0.089
Male smokers (n = 173) 0.96 0.70—1.31 0.165 0.94c 0.65—1.42 0.172
Male nonsmokers (n = 32) 0.64 0.32—0.97 0.032 0.62c 0.29—0.92 0.029
CI: conﬁdence interval; OR: odds ratio.
a Adjusted for age, sex, smoking status, diabetes, hypertension and dyslipidaemia.
b Adjusted for age, smoking status, diabetes, hypertension and dyslipidemia.
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iAdjusted for age, diabetes, hypertension and dyslipidemia.
eeded in various population contexts. The study of CETP
olymorphism in northern Africa provides a good oppor-
unity to focus attention on unknown aspects of coronary
therosclerosis. The key ﬁnding of this study is that the B2
llele of the CETP gene Taq1B polymorphism is associated
igniﬁcantly with an increase in HDL-C concentration and a
eduction in the prevalence of coronary artery disease.
The frequencies of the genotypes B1B1, B1B2 and B2B2
n our population with coronary artery disease were 49,
4 and 7%, respectively, with a B2 allele frequency of
.29. These results are similar to those reported else-
here in other populations, such as African—Americans,
here the B2 allele frequency was 0.26 [20]. However,
here have been reports of differences in the frequencies
f the B2 allele in other ethnic groups: the frequency of
he B2 allele was found to be 0.43, 0.44, 0.43 and 0.42 in
uropeans, Americans, Israelis and Taiwanese, respectively
13,16,26,27].
In our study, carriers of the B2 allele had a signiﬁ-
antly higher HDL-C concentration than those with the B1B1
enotype (p = 0.039). In a sex-based analysis, the effect of
he B2 allele on HDL-C seemed to be more signiﬁcant in
en (p < 0.001). Studies have shown that the B2B2 geno-
ype is associated with increased HDL-C concentrations and
ecreased risk of atherosclerosis and coronary artery disease
15,28]. The mechanism by which Taq1B polymorphism may
ffect HDL-C concentrations is not known. Taq1B polymor-
hism cannot be responsible solely for the change in HDL-C
oncentration, as it is a silent mutation and does not inﬂu-
nce CETP transcriptional regulation or sequence directly.
he slight increase in HDL-C concentration may be due to
ts linkage with other functional polymorphisms in the pro-
oter area of the gene, which may cause decreased activity
f CETP and hence, an increase in HDL-C concentration
29].
Human and transgenic mouse experiments have shown
hat environmental factors play an important role in the
odulation of CETP gene expression [30]. Various studies in
uman populations have analysed the possible interaction
etween environmental factors and the effect of the CETP
aq1B polymorphism on plasma HDL-C concentrations.
n this regard, we considered only the smoking habits
f patients, and observed that, in men, the correlation
etween the presence of the B2 allele and an increased
f
a
s
V
tDL-C concentration was stronger among nonsmokers than
mokers. In the west of Scotland coronary prevention
WOSCOP) study [28], the association of the Taq1B genotype
ith coronary artery disease was seen only in nonsmokers.
n contrast with our data, Fumeron et al. [12] did not ﬁnd
uch an interaction with tobacco smoking.
We also found that the B2 allele was associated signiﬁ-
antly with a 14% lower risk of signiﬁcant stenosis (OR 0.86,
5%CI: 0.7—0.96; p = 0.042), and that the association was
ore statistically signiﬁcant after adjustment for multiple
isk factors (age, sex, smoking status, diabetes, hyperten-
ion and dyslipidaemia).
The results of our study support the concept that
ncreased HDL-C concentrations appear to be associated
ith a lower risk of signiﬁcant stenosis in men. In fact, the
2 allele was associated with a 33% reduced risk of signiﬁ-
ant stenosis in men (OR 0.77, 95%CI: 0.57—0.91; p = 0.037),
nd this potential protective effect was more notable in
ale nonsmokers (38% reduced risk). Thus, the results of
ur study support the protective role of this genetic variant
gainst atherosclerosis and are concordant with other stud-
es reporting a lower risk for coronary heart disease among
arriers of the B2 allele [17,31].
Our data are in agreement with the regression growth
valuation statin study (REGRESS), the Framingham study,
he WOSCOP study and the veterans affairs HDL cholesterol
ntervention trial (VA-HIT) [15,16,28,32]. The B1B1 geno-
ype was associated with greater progression of coronary
therosclerosis in REGRESS and more cardiovascular end-
oints in VA-HIT than the B2B2 genotype. In each study,
1B1 individuals had lower HDL-C concentrations than B2B2
ndividuals. These data are inconsistent with those derived
rom the physicians’ health study where no association
etween the Taq1B polymorphism and myocardial infarction
as found [33].
There are some limitations to our study. Unfortunately,
ETP activity was not measured. Although many large-scale
tudies have reported an association between CETP activ-
ty and the Taq1B polymorphism [13—15], some have not
ound such an association [34]. In addition, we did not take
lcohol consumption into account because almost all of our
tudy population declared that they did not drink alcohol.
arious studies have reported that the association between
he CETP Taq1B polymorphism and HDL-C concentration was
[[
[
[
[
[
[
[
[
[
[
[
[
[
[CETP Taq1B polymorphism and coronary artery disease
more evident in alcohol consumers than in those who did not
drink alcohol [35,36].
In summary, the CETP Taq1B genotype was associated
with HDL-C concentration and the risk of coronary artery
disease in a Tunisian population. The B2 allele has a protec-
tive effect on coronary artery disease by increasing HDL-C
concentration. This protective effect seems to be more
signiﬁcant in male nonsmokers. CETP is expected to be a
potential target for the development of new pharmacolog-
ical agents that may raise serum HDL-C concentrations. It
will therefore be interesting to examine the relationship
between responses to such drugs and the genotypes of the
CETP gene.
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